Enhancements to the new edition support pharma and CROs to increase diversity in clinical trials, as well as align recruitment with disease incidence
HealthVerity has released its Provider Diversity Index (PDI) 2023 edition, which includes new enhancements such as age range, gender, income range, payer type (commercial, Medicare or Medicaid) and diagnosis.
First introduced in 2020, this nationally-syndicated report synchronizes medical, pharmacy and social determinants of health data from a large data ecosystem to calculate the racial diversity of patients for over 1 million physician practices, all in a HIPAA-compliant manner. The HealthVerity PDI is being used by pharma sponsors to identify clinical trial site investigators and to more effectively characterize and recruit patient populations that better reflect the diversity mix of diagnosed patients.
Alzheimer's is an example of a condition that disproportionately affects minorities. According to the Alzheimer's Association, 19% of Black/African American and 14% of Hispanic/Latino adults age 65 and older have Alzheimer's, compared to 10% of White/Caucasian seniors In contrast, participants in a 2020 clinical trial for an Alzheimer's medication were 86% White/Caucasian. Its PDI, says the company, could leverage diagnosis in a HIPAA-compliant manner to highlight physicians treating broader cohorts of minority patients whose recruitment could yield more effective clinical trial results.
"These statistics demonstrate how critical it is that researchers be able to work on clinical trials with physicians who have better access to patient populations representative of their particular study," said Andrew Kress, CEO of HealthVerity, in a press release.
Reference: HealthVerity releases the Provider Diversity Index 2023 edition to increase diversity in clinical trials. PHILADELPHIA, July 18, 2023. PRNewswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access